Benjamin P. Saylor

A 12-week randomized trial found a standardized saffron extract improved mood, self-esteem, and sleep outcomes in menopausal women vs placebo.

Among SWAN participants, sleep disturbance was independently associated with lower HRQoL relating to role-physical, role-emotional, and energy/fatigue, with no change in these associations over time.

Elinzanetant produced a numerically greater reduction in PSG-measured WASO vs placebo across the 12-week NIRVANA trial, with the effect more pronounced at week 4 than week 12.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

The total treatment effect of elinzanetant on sleep disturbance relative to placebo was -4.92 (95% CI, -5.73 to -4.12), indicating a clinically meaningful reduction.

Per CNN, Alito’s order is in effect until May 11, with responses to the case requested by Thursday, May 7.

The FDA has granted 510(k) clearance to Sibel Health’s ANNE Maternal, the first fully wireless platform for continuous, simultaneous maternal and fetal monitoring in labor, delivery, and the postpartum period.

The inserts, a formulation determined to be bioequivalent and therapeutically equivalent to the reference listed drug Endometrin (progesterone) vaginal inserts, 100 mg, are manufactured by Glenmark Pharmaceuticals Inc.

From FDA regulatory updates for products related to women's health, to a preview of upcoming annual meetings and conferences, we keep you updated on what's to come in Q2 of 2026.